Breast augmentation using implants is one of the most frequently performed aesthetic surgical procedures worldwide. It is considered to be a safe procedure, but requires general anesthesia and recovery can take time. The global aesthetic industry has been searching for a less invasive procedure to increase breast volume. Since 2018 a filler, Los Deline, is being used for breast augmentation. Surgeons at breast units in Stockholm have encountered and treated patients with complications after injections with this filler. The filler can cause breast deformities, infections and also has the ability to migrate. These complications can be severe and require several surgical treatments. We do not consider Los Deline to be a safe product for breast augmentation.
Download full-text PDF |
Source |
---|
Invasive Lobular Carcinoma (ILC), a distinct subtype of breast cancer is hallmarked by E-Cadherin loss, slow proliferation, and strong hormone receptor positivity. ILC faces significant challenges in clinical management due to advanced stage at diagnosis, late recurrence, and development of resistance to endocrine therapy - a cornerstone of ILC treatment. To elucidate the mechanisms underlying endocrine resistance in ILC, ILC cell lines (MDA-MB-134-VI, SUM44PE) were generated to be resistant to tamoxifen, a selective estrogen receptor modulator.
View Article and Find Full Text PDFAME Case Rep
December 2024
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Fibromatosis of the breast, also known as desmoid-type fibromatosis (DTF), is a rare tumor marked by the development of non-metastatic, locally aggressive tumors in breast tissue. It represents only 0.2% of all breast tumors.
View Article and Find Full Text PDFPharmaceutics
December 2024
Department of Experimental Therapeutics, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Surgery, National University Hospital, Singapore 119074, Singapore.
Background: In recent years, Artificial Intelligence (AI) has shown transformative potential in advancing breast cancer care globally. This scoping review seeks to provide a comprehensive overview of AI applications in breast cancer care, examining how they could reshape diagnosis, treatment, and management on a worldwide scale and discussing both the benefits and challenges associated with their adoption.
Methods: In accordance with PRISMA-ScR and ensuing guidelines on scoping reviews, PubMed, Web of Science, Cochrane Library, and Embase were systematically searched from inception to end of May 2024.
Curr Oncol
January 2025
Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu 610041, China.
Purpose: To evaluate the diagnostic value of ultrasound radiomics in distinguishing between benign and malignant breast nodules in women who have undergone silicone breast augmentation.
Methods: A retrospective study was conducted of 99 breast nodules detected by ultrasound in 93 women who had undergone silicone breast augmentation. The ultrasound data were collected between 1 January 2006 and 1 September 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!